3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Klatskin Tumor
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
32
Cisplatin
31
durvalumab
15
pembrolizumab
14
Fluorouracil
13
Oxaliplatin
12
Leucovorin
12
Capecitabine
10
Bevacizumab
8
lenvatinib
7
Nivolumab
7
zanidatamab
4
Trastuzumab
4
S 1 (combination)
4
Paclitaxel
4
Liquid Biopsy
4
Irinotecan
4
Carboplatin
4
Albumin-Bound Paclitaxel
4
tremelimumab
3
tislelizumab
3
irinotecan sucrosofate
3
Injections
3
Folfox protocol
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
niraparib
2
ivosidenib
2
envafolimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
gemcitabine-oxaliplatin regimen
×
1 year
×
Clear all
NCT05771480
2026-04-21
TOURMALINE
AstraZeneca
Phase 3
Active not recruiting
142 enrolled